ASND vs INCY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ASND · Ascendis Pharma A/S$252.73 ▼ 1.26%
INCY · Incyte$114.63 ▼ 1.07%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ASND +20.9%
- INCY +7.9%
Head to head
| Metric | ASND | INCY |
|---|---|---|
| Price | $252.73 | $114.63 |
| Change today | ▼ 1.26% | ▼ 1.07% |
| Market cap | $16.63B | $23.36B |
| Return, 3 months | +0.3% | -10.4% |
| Return, year to date | +18.5% | +16.1% |
| Return, 1 year | +16.4% | +12.3% |
| P/E (TTM) | 34.7 | 58.5 |
| P/B | 10.1 | 4.1 |
| P/E percentile vs own 5y | 100th | 79th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +73.0% | +14.0% |
| Net profit growth (YoY) | +221.3% | -285.0% |
| Gross margin | 91.9% | 92.7% |
| Operating margin | 31.3% | 11.7% |
| Net margin | 72.9% | 6.7% |
| Return on equity | 132.2% | 7.8% |
| Analyst target vs. price | +26.6% | +19.2% |
| Analyst buy share | 95% | 59% |
| RSI (14) | 49 | 42 |
| 30-day volatility | 28.6% | 32.5% |
| Max drawdown, 1 year | -19.7% | -18.3% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- INCY is the largest of the group by market value.
- ASND has returned the most over the past year.
- ASND carries the lowest trailing P/E.
- ASND is growing revenue fastest.
- ASND keeps the most profit per dollar of sales.
- ASND has been the calmest stock over the last 30 days.